TSE Code 4502 TSE 1st.
Ticker Symbol TAK.
Recent Releases.
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting.
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan.
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS.
Takeda Accelerates Digital Transformation with Accenture and AWS.
Related Content.
Share Graph.
This website contains forward-looking statements regarding the Company’s plans, outlook, strategies, and results for the future. All forward-looking statements are based on the judgments derived from the information available to the Company at the time of issuance of this site.
All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward-looking statements can sometimes be identified by the use of forward-looking words such as «may,» «believe,» «will,» «expect,» «project,» «estimate,» «should,» «anticipate,» «plan,» «continue,» «seek,» «pro forma,» «potential,» «target, » «forecast,» or «intend,» or other similar words or expressions of the negative thereof.
Certain risks and uncertainties could cause the Company’s actual results to differ materially from any forward-looking statements contained in this presentation. These risks and uncertainties include, but are not limited to,
(1) the economic circumstances surrounding the Company’s business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; (8) integration activities with acquired companies.
We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.
The information on this website is provided for informational purposes and should not be construed as a solicitation of an investment in our securities.
You should rely on your own independent examination of us before investing in any securities issued by our company.